Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment

When an E/M visit is billed on the same day as an IV iron infusion, Modifier 25 is required on the E/M code to indicate a significant, separately identifiable evaluation and management service
After 2 weeks of treatment, mice treated with GLP-1MK-801, as well as those subjected to calorie restriction or GLP-1 monotherapy, demonstrated enhanced glucose tolerance compared with mice that were treated with the vehicle or MK-801 monotherapy (Extended Data Fig
Add High-Protein Eating Suggestions Aim for 2030g protein each meal: Eggs Greek yogurt Chicken, turkey, fish Protein shakes Lentils, beans, chickpeas Protein balances blood sugar and prevents GLP-1-related fatigue